OMGA RSI Chart
Last 7 days
23.0%
Last 30 days
-5.9%
Last 90 days
-43.8%
Trailing 12 Months
-72.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 4.9M | 0 | 0 | 0 |
2023 | 2.3M | 2.6M | 2.8M | 3.1M |
2022 | 626.4K | 1.1M | 1.6M | 2.1M |
2021 | 0 | 0 | 0 | 144.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 02, 2023 | young richard a | sold | -40,000 | 8.00 | -5,000 | - |
May 01, 2023 | young richard a | sold | -40,000 | 8.00 | -5,000 | - |
Apr 06, 2023 | young richard a | sold | -40,000 | 8.00 | -5,000 | - |
Mar 17, 2023 | young richard a | sold | -80,000 | 8.00 | -10,000 | - |
Feb 27, 2023 | flagship pioneering inc. | bought | 11,525,200 | 5.78 | 1,993,990 | - |
Feb 27, 2023 | flagship pioneering inc. | bought | 7,683,490 | 5.78 | 1,329,320 | - |
Jan 10, 2023 | young richard a | sold | -160,000 | 8.00 | -20,000 | - |
Sep 14, 2022 | young richard a | sold | -80,000 | 8.00 | -10,000 | - |
Feb 01, 2022 | karande mahesh | acquired | 5,989 | 0.53 | 11,300 | president and ceo |
Aug 03, 2021 | berry david a | bought | 902,394 | 17.00 | 53,082 | - |
Which funds bought or sold OMGA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | unchanged | - | 846,885 | 4,830,880 | 0.12% |
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -94,096 | - | -% |
May 16, 2024 | Colony Group, LLC | new | - | 25,000 | 25,000 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.92 | -3,130 | 8,943 | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 217,346 | 217,346 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 1,137 | 1,114,520 | 1,194,080 | -% |
May 15, 2024 | AMUNDI | sold off | -100 | -110,921 | - | -% |
May 15, 2024 | Flagship Pioneering Inc. | unchanged | - | 18,704,400 | 106,673,000 | 7.00% |
May 15, 2024 | 683 Capital Management, LLC | unchanged | - | 73,600 | 419,750 | 0.03% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 26.82 | 6,556 | 18,743 | -% |
Unveiling Omega Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Omega Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Omega Therapeutics, Inc. News
Income Statement (Quarterly) | |||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 138.7% | 2,360 | 989 | 831 | 759 | 516 | 735 | 595 | 476 | 268 | - |
Operating Expenses | 5.2% | 22,811 | 21,688 | 23,734 | 31,599 | 26,334 | 31,702 | 26,580 | 26,330 | 20,227 | 20,808 |
S&GA Expenses | -100.0% | - | 6,157 | 7,869 | 6,206 | 5,954 | 7,036 | 5,198 | 6,202 | 5,406 | 5,727 |
R&D Expenses | -1.9% | 15,415 | 15,715 | 16,475 | 25,012 | 19,968 | 26,879 | 20,670 | 19,387 | 14,191 | 14,644 |
Interest Expenses | -32.0% | 331 | 487 | 684 | 957 | 682 | 248 | 184 | -55.00 | -155 | -571 |
Net Income | 0.4% | -20,129 | -20,214 | -22,248 | -29,687 | -25,279 | -30,826 | -25,799 | -25,912 | -20,164 | -20,854 |
Net Income Margin | 40.7% | -18.69* | -31.48* | -38.04* | -42.85* | -46.44* | -49.53* | -58.28* | -77.08* | -119.67* | -474.17* |
Free Cashflow | 32.3% | -12,335 | -18,211 | -23,724 | -23,581 | -28,403 | -24,529 | -25,163 | -26,701 | -23,502 | -16,156 |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -10.1% | 184 | 204 | 218 | 229 | 156 | 146 | 170 | 193 | 217 | 233 | 243 | 130 | 28.00 |
Current Assets | -21.1% | 71.00 | 90.00 | 102 | 125 | 149 | 138 | 161 | 183 | 206 | 229 | 239 | 125 | 24.00 |
Cash Equivalents | -12.3% | 60.00 | 68.00 | 82.00 | 106 | 105 | 71.00 | 77.00 | 91.00 | 106 | 186 | 234 | 122 | 23.00 |
Net PPE | -5.6% | 5.00 | 5.00 | 5.00 | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 |
Liabilities | -2.7% | 142 | 146 | 142 | 133 | 33.00 | 40.00 | 36.00 | 36.00 | 36.00 | 33.00 | 23.00 | 22.00 | 17.00 |
Current Liabilities | -7.9% | 25.00 | 27.00 | 27.00 | 34.00 | 18.00 | 22.00 | 15.00 | 14.00 | 14.00 | 12.00 | 14.00 | 12.00 | 8.00 |
Long Term Debt | -6.6% | 14.00 | 15.00 | 16.00 | 12.00 | 14.00 | 17.00 | 20.00 | 20.00 | 20.00 | 20.00 | 7.00 | 9.00 | 9.00 |
LT Debt, Current | 0% | 4.00 | 4.00 | 4.00 | 8.00 | 6.00 | 3.00 | - | - | - | - | 5.00 | 3.00 | 3.00 |
LT Debt, Non Current | -100.0% | - | 15.00 | 16.00 | 12.00 | 14.00 | 17.00 | 20.00 | 20.00 | 20.00 | 20.00 | 7.00 | 9.00 | 9.00 |
Shareholder's Equity | -28.7% | 41.00 | 58.00 | 76.00 | 96.00 | 123 | 106 | 134 | 157 | 181 | 201 | 220 | - | - |
Retained Earnings | -6.0% | -354 | -334 | -314 | -292 | -262 | -237 | -206 | -180 | -154 | -134 | -113 | -95.12 | -66.22 |
Additional Paid-In Capital | 0.9% | 396 | 393 | 390 | 388 | 386 | 344 | 341 | 339 | 337 | 335 | 334 | 3.00 | 2.00 |
Shares Outstanding | 0.0% | 55.00 | 55.00 | 55.00 | 55.00 | 55.00 | 48.00 | 48.00 | 48.00 | 48.00 | 48.00 | 14.00 | 5.00 | - |
Float | - | - | - | - | 140 | - | - | - | 80.00 | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | 31.0% | -11,800 | -17,100 | -23,000 | -23,289 | -28,111 | -24,237 | -24,835 | -26,093 | -23,350 | -15,956 | -16,496 | -14,608 | -10,549 | - | - | - |
Share Based Compensation | 62.4% | 3,431 | 2,113 | 2,280 | 2,178 | 2,222 | 2,122 | 1,974 | 2,053 | 1,604 | 1,182 | 1,123 | 685 | 194 | - | - | - |
Cashflow From Investing | 108.6% | 4,465 | 2,140 | -724 | 24,049 | 22,050 | 17,652 | 10,588 | 11,267 | -57,567 | -39,132 | -353 | -866 | -48.00 | - | - | - |
Cashflow From Financing | -165.8% | -1,070 | 1,625 | -8.00 | 219 | 39,987 | 586 | 4.00 | 35.00 | 83.00 | 7,295 | 128,713 | 118 | 125,413 | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Collaboration revenue | $ 2,360 | $ 516 |
Operating expenses: | ||
Research and development | 15,415 | 20,091 |
General and administrative | 7,396 | 6,243 |
Total operating expenses | 22,811 | 26,334 |
Loss from operations | (20,451) | (25,818) |
Other Income (expense), net: | ||
Interest income, net | 331 | 682 |
Other expense, net | (9) | (143) |
Total other income, net | 322 | 539 |
Net loss | $ (20,129) | $ (25,279) |
Net loss per common stock attributable to common stockholders, basic | $ (0.36) | $ (0.5) |
Net loss per common stock attributable to common stockholders, diluted | $ (0.36) | $ (0.5) |
Weighted-average common stock used in net loss per share attributable to common stockholders, basic | 55,150,507 | 50,627,287 |
Weighted-average common stock used in net loss per share attributable to common stockholders, diluted | 55,150,507 | 50,627,287 |
Comprehensive loss: | ||
Net Income (Loss) | $ (20,129) | $ (25,279) |
Other comprehensive income (loss): | ||
Unrealized gain on marketable securities | 14 | 251 |
Comprehensive loss | $ (20,115) | $ (25,028) |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 60,033 | $ 68,443 |
Marketable securities | 4,986 | |
Accounts receivable, due from related party | 1,149 | 1,006 |
Accounts receivable | 5,125 | |
Prepaid expenses and other current assets | 9,708 | 10,324 |
Total current assets | 70,890 | 89,884 |
Property and equipment, net | 5,013 | 5,311 |
Operating lease right-of-use assets, net | 107,362 | 108,736 |
Restricted cash | 341 | 341 |
Other assets | 74 | 94 |
Total assets | 183,680 | 204,366 |
Current liabilities: | ||
Accounts payable | 1,579 | 1,620 |
Accrued expenses | 4,492 | 7,914 |
Other current liabilities | 2,620 | 1,972 |
Lease liabilities, current | 11,989 | 11,300 |
Long-term debt, current portion | 4,000 | 4,000 |
Total current liabilities | 24,680 | 26,806 |
Lease liabilities, non-current | 97,729 | 98,243 |
Long-term debt, net | 13,897 | 14,885 |
Other liabilities | 6,020 | 6,416 |
Total liabilities | 142,326 | 146,350 |
Commitments and contingencies (Note 9) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 55,154,985 and 55,144,982 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 55 | 55 |
Additional paid-in capital | 396,062 | 392,609 |
Accumulated other comprehensive loss | (14) | |
Accumulated deficit | (354,763) | (334,634) |
Total stockholders' equity | 41,354 | 58,016 |
Total liabilities and stockholders' equity | $ 183,680 | $ 204,366 |